IFP Advisors Inc Buys 2,348 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

IFP Advisors Inc grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 96.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,777 shares of the biopharmaceutical company’s stock after acquiring an additional 2,348 shares during the period. IFP Advisors Inc’s holdings in Intra-Cellular Therapies were worth $399,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its position in shares of Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after acquiring an additional 2,157 shares during the period. Barclays PLC grew its position in shares of Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after acquiring an additional 25,435 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Intra-Cellular Therapies by 31.9% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock valued at $33,258,000 after acquiring an additional 109,892 shares during the period. Oak Ridge Investments LLC grew its position in shares of Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after acquiring an additional 8,440 shares during the period. Finally, Cynosure Group LLC grew its position in shares of Intra-Cellular Therapies by 161.0% during the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock valued at $1,057,000 after acquiring an additional 8,909 shares during the period. 92.33% of the stock is owned by institutional investors.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $128.20 on Friday. Intra-Cellular Therapies, Inc. has a 1 year low of $63.30 and a 1 year high of $129.00. The stock has a market capitalization of $13.63 billion, a PE ratio of -147.35 and a beta of 0.72. The company’s 50 day simple moving average is $114.58 and its two-hundred day simple moving average is $91.50.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, JPMorgan Chase & Co. upped their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and an average price target of $106.08.

Insider Activity

In other news, CEO Sharon Mates sold 51,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.